# US 2024/0182422 A1 · Preparation method of quinoline derivative compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0182422 A1
- Document ID: US20240182422A1
- Status: Published application
- Kind: A1
- Application number: 18/284,253
- Filed: 2022-03-23
- Published: 2024-06-06
- Earliest claimed: 2021-03-26
- Assignees: Abivax; Centre National De La Recherche Scientifique; Universite De Montpellier; Institut Curie
- Applicants: Abivax; Centre National De La Recherche Scientifique; Universite De Montpellier; Institut Curie
- Inventors: Jérôme DENIS; Fabien DE BLASIO; Thierry BOYER; Charles GUERIN; Julien MICHAUX; Romain NAJMAN; Florence MAHUTEAU-BETZER
- Web page: https://patentgrep.com/patent/US20240182422A1

## CPC

- C07D 215/38: Nitrogen atoms (nitro radicals C07D215/18)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

A method for preparing a compound of formula (I), a powder, and a pharmaceutical composition are disclosed. The method includes: (i) reacting a compound of formula (II) with a compound of formula (III), to form the hydrochloride salt of the compound of formula (I), and (ii) recovering the compound of formula (I) in the form of a free base through addition of a base. In step (i), the molar ratio of the compound of formula (II) to the compound of formula (III) is in a range of from 1.00:0.80 to 1.00:1.20, and no metal catalyst is present. A powder including the composition of formula (I) may be obtained by the method. The powder may have a particle size distribution with specific D50, D90 and/or D10 values. A pharmaceutical composition may include the powder and at least one pharmaceutically acceptable excipient.

## Claims

### Claim 1

A method for preparing a compound of formula (I)
wherein
R is selected from a (C1-C3)alkyl group, a (C1-C3)alkoxy group, a (C1-C3)fluoroalkyl group, a halogen atom, a (C1-C3)fluoroalkoxy group, and a —NR1R2 group, where R1 and R2 are independently a hydrogen atom or a (C1-C3)alkyl group,
R′ represents a halogen atom or a methyl group, and
R″′ represents a hydrogen atom or a
group,
wherein
A is O or NH,
m is 2 or 3, and
X1 is —O—, —CH2— or —N(Ra)—, where Ra is a (C1-C3)alkyl group,
the method comprising:
(i) reacting a compound of formula (II)
with a compound of formula (III)
to form a hydrochloride salt of the compound of formula (I),
wherein a molar ratio of the compound of formula (II) to the compound of formula (III) is in a range of from 1.00:0.80 to 1.00:1.20, and no metal catalyst is present, and then
(ii) recovering the compound of formula (I) in the form of a free base through addition of a base.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the compound of formula (II) is prepared by chlorination of a compound of formula (IV)

### Claim 3 (depends on 2)

The method according to claim 2, wherein the compound of formula (IV) is prepared by cyclizing a compound of formula (V)
wherein
R″ represents a halogen atom or a (C1-C3)alkyl group, and
n is 1 or 2.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the compound of formula (V) is prepared by amidation of a compound of formula (VI)
with a compound of formula (VI′)

### Claim 5 (depends on 4)

The method according to claim 4, wherein the compound of formula (VI) is prepared by conversion of a carboxylic acid function of a compound of formula (VII) into an acyl chloride function

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The method according to claim 1, wherein hydrochloric acid is added during step (i).

### Claim 8 (depends on 1)

The method according to claim 1, wherein seeds of the hydrochloride salt of the compound of formula (I) are added during step (i).

### Claim 9 (depends on 1)

The method according to claim 1, wherein an acid is added near the beginning of step (i), said acid being selected from the group consisting of:
hydrochloric acid, hydrobromic acid, sulfuric acid, perchloric acid, phosphoric acid, trifluoroacetic acid, acetic acid, citric acid, oxalic acid, maleic acid, tartaric acid, succinic acid, malonic acid and mixtures thereof.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the molar ratio of the compound of formula (II) to the compound of formula (III) is in a range of from 1.00:0.80 to 1.00:1.10.

### Claim at position 11

11-12. (canceled)

### Claim 13 (depends on 1)

The method according to claim 1, wherein at least one of (a) and (b) is satisfied:
(a) step (i) is carried out in an organic solvent selected from the group consisting of ethyl acetate, isopropyl acetate, toluene, N,N-dimethylformamide (DMF), N-methyl-2-pyrrolidone (NMP), a (C1-C4)alcohol, and mixtures thereof, and
(b) step (i) is carried out at a reaction temperature ranging from 60° C. to 120° C.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The method according to claim 1, further comprising at least one of (a) and (b):
(a) performing one or more purification steps, and
(b) crystallizing the compound of formula (I) using at least one solvent.

### Claim 16 (depends on 5)

The method according to claim 5, wherein the conversion of the carboxylic function into the acyl chloride function is carried out by using a chlorination agent selected from the group consisting of SOCl2, PCl3, POCl3, and PCl5, and optionally in a solvent.

### Claim 17

(canceled)

### Claim 18 (depends on 3)

The method according to claim 3, wherein the cyclizing is carried out by using:
chlorobenzene, trifluorotoluene, fluorobenzene, toluene, dichloroethane, or a mixture thereof, and
a Lewis acid selected from the group consisting of aluminum chloride (AlCl3), BF3, trifluoromethanesulfonic acid, titanium chloride, and methanesulfonic acid.

### Claim 19 (depends on 2)

The method according to claim 2, wherein the chlorination is carried out by using a chlorination agent selected from the group consisting of SOCl2, PCl3, POCl3, and PCl5, and optionally by using a solvent.

### Claim 20 (depends on 1)

The method according to claim 1, wherein:
the compound of formula (I) is 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine,
the compound of formula (III) is 4-trifluoromethoxyaniline, and
the compound of formula (II) is compound (3):

### Claim 21 (depends on 5)

The method according to claim 5, wherein:
the compound of formula (I) is 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine
the compound of formula (III) is 4-trifluoromethoxyaniline,
the compound of formula (II) is compound (3):
the compound of formula (IV) is compound (2):
the compound of formula (V) is compound (1):
the compound of formula (VI) is the following compound
the compound of formula (VI′) is 2-chloro-aniline, and
the compound of formula (VII) is the following compound

### Claim 22 (depends on 1)

The method according to claim 1, wherein the compound of formula (I) is 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine in crystalline Form I having at least one of (1) and (2):
(1) a melting point of 120.5° C. (±2° C.), and
(2) an XRPD analysis showing
(a) the following main peaks expressed as degree 2-Theta angles by a XRPD analysis: 7.3, 14.6, 23.5, and 28.4 (each time ±0.2), optionally further showing the following additional peaks: 12.1, 17.3, 18.4, 23.0; 24.2, 24.9, 27.4 and 29.1 (each time ±0.2), and optionally even further showing the following additional peaks: 13.7, 16.3, 16.9, 18.1, 22.4, and 29.6 (each time ±0.2);
(b) the signals listed in Table 1; or
(c) a spectrum substantially the same as FIG. 1.

### Claim 23 (depends on 1)

The method according to claim 1, further comprising:
milling the compound of formula (I) obtained from step (ii) in order to obtain a milled compound of formula (I), or
crystallizing the compound of formula (I) obtained from step (ii) to obtain a crystallized compound of formula (I) and then milling the crystallized compound of formula (I) in order to obtain a milled crystallized compound of formula (I).

### Claim 24 (depends on 1)

The method according to claim 1, further comprising preparing a pharmaceutical composition comprising the compound of formula (I), with pharmaceutically acceptable excipients.

### Claim 25 (depends on 23)

Powder obtained by the method according to claim 23 after the milling.

### Claim 26 (depends on 25)

The powder according to claim 25, wherein said powder has at least one of (1), (2), and (3):
(1) a particle size distribution having a D50 value of not more than 80.0 μm,
(2) a particle size distribution having a D10 value of not more than 20.0 μm, and
(3) a particle size distribution having a D90 of not more than 190.0 μm.

### Claim at position 26

27-28. (canceled)

### Claim 29

Powder comprising a compound of formula (I)
wherein
R is selected from a (C1-C3)alkyl group, a (C1-C3)alkoxy group, a (C1-C3)fluoroalkyl group, a halogen atom, a (C1-C3)fluoroalkoxy group, and a —NR1R2 group, where R1 and R2 are independently a hydrogen atom or a (C1-C3)alkyl group,
R′ represents a halogen atom or a methyl group, and
R″′ represents a hydrogen atom or a
group,
wherein
A is O or NH,
m is 2 or 3, and
X1 is —O—, —CH2— or —N(Ra)—, where Ra is a (C1-C3)alkyl group,
wherein said powder has at least one of (1), (2), and (3):
(1) a particle size distribution having a D50 value of not more than 80.0 μm,
(2) a particle size distribution having a D10 value of not more than 20.0 μm, and
(3) a particle size distribution having a D90 value of not more than 190.0 μm.

### Claim at position 28

30-31. (canceled)

### Claim 32 (depends on 25)

A pharmaceutical composition comprising the powder according to claim 25 and at least one pharmaceutically acceptable excipient.

### Claim 33

(canceled)
